ROIV Projected Dividend Yield
Ord/Roivant Sciences Ltd ( NASDAQ : ROIV )Roivant Sciences develops drug candidates in subsidiary companies Co. calls Vants. Co.'s Vants and pipeline include Dermavant Sciences Ltd., which is developing tapinarof for the treatment of psoriasis and atopic dermatitis, with an earlier-stage development pipeline; Immunovant, Inc., which is developing IMVT-1401 for the treatment of Myasthenia Gravis, Warm Autoimmune Hemolytic Anemia and Thyroid Eye Disease; Aruvant Sciences Ltd., which is developing ARU-1801 as a one-time, potentially curative gene therapy for the treatment of sickle cell disease; and Proteovant Sciences, Inc, which is developing heterobifunctional protein degraders for oncology, neurology, and immunology AR Degrader. 20 YEAR PERFORMANCE RESULTS |
ROIV Dividend History Detail ROIV Dividend News ROIV Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |